EU Body Backs AstraZeneca, Bristol Diabetes Drug That the U.S. Rejected

Advisers to the European drug regulator recommended approval of an experimental diabetes drug that was rejected by U.S. regulators earlier this year amid concerns about its safety. Shares of the drug’s co-developers, Bristol-Myers Squibb and AstraZeneca, rose after the recommendation, which surprised some analysts who had largely written off the drug, dapagliflozin, after the U.S. rejection.
Fox Business